CTMX — CytomX Therapeutics Inc

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

About CytomX Therapeutics Inc

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increa… Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$3.69
Market Cap$828M
Float189.5M
Shares Outstanding217.7M
P/E (Forward)14.20
Price/Sales (TTM)23.31
vs. Analyst Target+233.3% to analyst PT
Profit Margin-166.40%
Operating Margin (TTM)-191.77%
Revenue (TTM)$35.5M
Earnings Growth (YoY)60.60%
Dividend RateNone
Analyst Target Price$12.30 (6 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 $68.4M -$64.8M $68.4M -$78.0M
2021 $69.6M -$80.6M $69.6M -$81.1M
2022 $53.2M -$97.3M $53.2M -$98.9M
2023 $101M -$569,000 $101M -$4.3M
2024 $138M $31.9M $138M $26.8M
2025 $76.2M -$17.4M $76.2M -$21.0M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Jun 2025 $18.7M -$154,000
Sep 2025 $6.0M -$14.2M
Dec 2025 $663,000 -$26.5M
Mar 2026 $10.3M -$18.2M

Ownership & Float

Insider Ownership0.6%
Institutional Ownership96.2%
Short Float15.7%
% of All Funds Holding1.93%
Number of Funds Holding159

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$4.19Near-term / short-term trend
Weekly40-Week SMA$4.07Medium-term trend
Weekly80-Week SMA$2.74Cyclical trend (business cycle)
Weekly200-Week SMA$2.07Secular trend (multi-year)
Monthly10-Month SMA$4.10Near-term monthly trend
Monthly20-Month SMA$2.71Medium-term monthly trend
Monthly40-Month SMA$2.15Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$2.10 support 1.33x 7 months ago
$0.80 support 4.91x 11 months ago

Historical Earnings Reactions (43 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap -1.49% 0.00% 46.51% 15.07% -35.04%
1 Day -0.38% -0.25% 48.84% 25.10% -51.31%
1 Week -4.46% -1.63% 46.51% 38.13% -52.27%
2 Weeks -2.90% 0.62% 51.16% 45.53% -56.32%
1 Month -1.87% -0.53% 50.00% 36.81% -64.44%

Next earnings: July 26, 2026 (60 days away)

Seasonality & Day-of-Week Patterns

Monthly Seasonality

MonthAvg ReturnWin RateSamples
Jan9.5%63.6%11
Feb-2.9%36.4%11
Mar-4.2%18.2%11
Apr-1.8%45.5%11
May19.6%40.0%10
Jun-3.6%40.0%10
Jul-4.9%30.0%10
Aug-1.6%40.0%10
Sep3.5%30.0%10
Oct-7.0%30.0%10
Nov17.8%81.8%11
Dec0.4%45.5%11

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday 0.44% 48.3% 499
Tuesday -0.17% 44.4% 550
Wednesday 0.55% 47.5% 547
Thursday -0.55% 45.1% 537
Friday 0.41% 53.8% 537

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 96.2%

Insider Transactions — Smart Summary

Total insider ownership: 0.6%

12-Month Insider Activity Summary

Total Filings8
Net Value-$1.9M
Net Shares Change-149,506
% of Float-0.1%
C-Suite Filings8
Clusters Detected2

Key Insiders

NameTitleNet ValueFilingsActivity
McCarthy Sean A. CEO -$1.4M 3 1 sell
BELVIN MARCIA SVP, Chief Scientific Officer -$239,607.192 2 2 sell
Ogden Christopher Chief Financial Officer -$157,493.024 2 2 sell
Chu Yu-Waye Chief Medical Officer -$136,675.017 1 1 sell

Transaction Clusters

PeriodFilingsInsidersNet ValueSeniority
2025-06-17 – 2025-06-17 3 3 -$219,978.998 3 C-suite
2026-03-19 – 2026-03-19 4 4 -$1.2M 4 C-suite

Significant Filings

DateInsiderTitleNet ValuePrice After
2026-03-19 Chu Yu-Waye Chief Medical Officer -$136,675.017 Transaction at $6.42, now -42.6%
2026-03-19 Ogden Christopher Chief Financial Officer -$124,111.629 Transaction at $6.42, now -42.6%
2026-03-19 BELVIN MARCIA SVP, Chief Scientific Officer -$202,273.116 Transaction at $6.42, now -42.6%
2025-06-17 Ogden Christopher Chief Financial Officer -$33,381.395 Transaction at $2.72, now +35.5%
2025-06-17 McCarthy Sean A. CEO -$149,263.528 Transaction at $2.69, now +37.2%
2025-06-17 BELVIN MARCIA SVP, Chief Scientific Officer -$37,334.076 Transaction at $2.69, now +37.2%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for CytomX Therapeutics Inc (CTMX) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for CTMX on Trend Edge →